The Food and Drug Administration has reversed its prior opposition to UniQure’s experimental Huntington’s disease treatment AMT-130 and told the company it may pursue a U.S. marketing application, UniQure said; the company plans to file in the third quarter.
At a recent meeting, FDA officials agreed that a three-year analysis of an early-stage study showing a benefit for patients was "acceptable" to support a marketing application, UniQure said, and the company is seeking accelerated approval for AMT-130.
That determination is the immediate consequence: UniQure can prepare a formal filing in the United States and expects to submit a marketing application in the third quarter, the company said on Wednesday. For patients and clinicians who have followed AMT-130’s progress, the change replaces regulatory roadblocks with a clear timetable.
AMT-130 is an investigational gene therapy for Huntington’s disease. Until the recent meeting, the agency had signaled resistance to using the available long-term, early-stage data as the basis for an approval. The FDA’s reversal followed direct discussions with UniQure officials about the three-year dataset and its implications for accelerated approval.
The U-turn highlights a sharp contradiction in how the same evidence has been judged. Previously, former FDA officials Marty Makary and Vinay Prasad concluded the AMT-130 data were insufficient to support a marketing application. Their assessment underscored skepticism among some who viewed the trial dataset as too limited to justify approval without further study.
UniQure’s announcement does not resolve that dispute. The company now moves from regulatory limbo to an explicit filing plan, but whether the FDA will grant accelerated approval on the basis of the three-year analysis remains unresolved. An accelerated pathway would typically demand that the benefit demonstrated is meaningful and that confirmatory post-approval studies are feasible; those judgments will fall to reviewers once a formal submission is in hand.
Investors and patient advocates will be watching qure stock and the dossier UniQure assembles. The firm’s decision to seek accelerated approval ties the company’s near-term prospects directly to how persuasive the three-year results are to FDA reviewers and whether the agency accepts the proposed regulatory package.
UniQure’s next concrete step is set: a marketing application in the third quarter. After that, the critical question is procedural and scientific, not calendar-bound—will the FDA accept accelerated approval on the basis of the three-year analysis when it evaluates the formal submission? The answer will determine whether AMT-130 advances to patients under an accelerated pathway or faces further evidentiary demands before any U.S. authorization.
